MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why XERS Stock advanced +1.03% Today — RQD Quant Desk Flash
$10.75 +1.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.75
Xeris Biopharma Holdings Inc. (XERS) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $1.96B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.75 (+0.00%)🧬 Disciplined Float (+0.24% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 9.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XERS)Realized 20D OHLCV Swing Band: ±10.4%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY XERS SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 9.8% FCF Margin ($28.6M FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (19% of score)
20D Institutional Volume Accumulation (±10.4% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution11/20 pts (-9 pt drag)
Disciplined Float (+0.24% YoY Shares) & executive Form 4 sales trim 9 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$10.48-1.6% Next Q
54
Q2 (-2Q)Grade C$10.31-1.1% Next Q
57
Q3 (-1Q)Grade C$10.20+5.4% Next Q
59
CurrentGrade C$10.75+0.7% Hist 90D α
62
Trajectory: C- (54) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the XERS Bull Thesis Could Fail
Even with a 62/100 (C) score, XERS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (+0.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.31) or 200D SMA ($7.50) invalidates the momentum regime and cuts Target Base ($10.94) toward Bear Floor ($8.53).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $XERS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XERS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why XERS Stock advanced +1.03% Today — RQD Quant Desk Flash
Xeris Biopharma Holdings Inc. (XERS) advanced +1.03% to $10.75, trading at 89% of its 52-week range ($5.25 – $11.42). Solid steady margins (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 89% of its 52-week range ($5.25 – $11.42) with RSI-14 at 60 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.4% around $10.75 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $28.6M annual free cash flow.
Live XERS Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (XERS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
XERS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +75.37%▲ ASCENDING CHANNEL
2026-10-30O $10.81H $10.88L $10.52C $10.75VOL 1.55M
RES: $12.23SUP: $8.21SMA50: $9.31SMA200: $7.50
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
XERS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +43.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on XERS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for XERS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XERS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XERS)
Health Care Rank #168 of 1016
⚔️ TRVI vs XERS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (XERS vs. TRVI, BRVE, ADRX, TRAX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Xeris Biopharma Holdings Inc. (XERS) ranks #168 by composite RQD confidence (62/100, grade C) and #267 by equity capitalization ($1.96B). Within this direct 5-issuer industry benchmark cohort, XERS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XERS
ACTIVE
Xeris Biopharma Holdings Inc. | C | 62/100 | — | — | 16.0% | +1.03% | $1.96B | Benchmark Subject |
| TRVI Trevi Therapeutics Inc. | D- | 39/100 | — | — | -23.7% | +2.15% | $1.97B | /trvi-vs-xers → |
| BRVE Braveheart Bio Inc. | D | 47/100 | — | — | — | -2.62% | $1.91B | /brve-vs-xers → |
| ADRX ADARx Pharmaceuticals Inc. | D+ | 52/100 | — | — | — | -0.56% | $1.91B | /adrx-vs-xers → |
| TRAX First Tracks Biotherapeutics Inc. | E | 33/100 | — | — | -35.0% | -1.08% | $1.90B | /trax-vs-xers → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001867096In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xeris Biopharma Holdings Inc. (XERS) reported GAAP revenue of $291.8M (+43.7% vs. FY2024 revenue of $203.1M , and +78.0% cumulative change since FY2023) , GAAP net income of $554.0K, operating cash flow of $28.6M, and free cash flow of $28.6M (+177.4% YoY). On the balance sheet, XERS closed FY2025 with $383.5M in total assets against $220.3M in total debt (Altman Z-Score: 2.11, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $291.8M | $554.0K | $28.6M | $28.6M | $383.5M | $220.3M |
| FY2024 (FY) | 2024-12-31 | $203.1M | -$54.8M | -$37.0M | -$37.0M | $323.1M | $217.0M |
| FY2023 (FY) | 2023-12-31 | $163.9M | -$62.3M | -$47.0M | -$47.0M | — | — |
3. XERS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs XERS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Xeris Biopharma Holdings Inc. (NASDAQ: XERS) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $10.75 (+1.03% 1D, market cap $1.96B). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, XERS ranks #168 in composite RQD confidence.
How does XERS compare to TRVI and BRVE in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XERS carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 16.0%. By comparison, TRVI (Trevi Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -23.7%, cap $1.97B) and BRVE (Braveheart Bio Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $1.91B). Among the 5-stock peer group, XERS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for XERS?
Per XERS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001867096), Xeris Biopharma Holdings Inc. generated $291.8M in revenue (+43.7% YoY), $554.0K in net income, and $28.6M in free cash flow against $383.5M in total assets and $220.3M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is XERS trading relative to its 50-day, 200-day, and 52-week technical levels?
XERS last traded at $10.75 (+1.03% on volume of 1,745,572 shares), positioning the stock +15.47% above its 50-day simple moving average ($9.31) and +43.33% above its 200-day simple moving average ($7.50). Across its 52-week range of $5.25 to $11.42, XERS sits at the 89.1% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($9.63 to $11.87).
XERS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is XERS stock moving today?
Why XERS Stock advanced +1.03% Today — RQD Quant Desk Flash. Solid steady margins (16% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.